Antibodies, Monoclonal, Humanized
"Antibodies, Monoclonal, Humanized" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab.
| Descriptor ID |
D061067
|
| MeSH Number(s) |
D12.776.124.486.485.114.224.060 D12.776.124.790.651.114.224.060 D12.776.377.715.548.114.224.200
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Antibodies, Monoclonal, Humanized".
- Chemicals and Drugs [D]
- Amino Acids, Peptides, and Proteins [D12]
- Proteins [D12.776]
- Blood Proteins [D12.776.124]
- Immunoproteins [D12.776.124.486]
- Immunoglobulins [D12.776.124.486.485]
- Antibodies [D12.776.124.486.485.114]
- Antibodies, Monoclonal [D12.776.124.486.485.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.486.485.114.224.060]
- Serum Globulins [D12.776.124.790]
- Immunoglobulins [D12.776.124.790.651]
- Antibodies [D12.776.124.790.651.114]
- Antibodies, Monoclonal [D12.776.124.790.651.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.124.790.651.114.224.060]
- Globulins [D12.776.377]
- Serum Globulins [D12.776.377.715]
- Immunoglobulins [D12.776.377.715.548]
- Antibodies [D12.776.377.715.548.114]
- Antibodies, Monoclonal [D12.776.377.715.548.114.224]
- Antibodies, Monoclonal, Humanized [D12.776.377.715.548.114.224.200]
Below are MeSH descriptors whose meaning is more specific than "Antibodies, Monoclonal, Humanized".
This graph shows the total number of publications written about "Antibodies, Monoclonal, Humanized" by people in this website by year, and whether "Antibodies, Monoclonal, Humanized" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1998 | 0 | 1 | 1 |
| 2002 | 0 | 4 | 4 |
| 2003 | 0 | 2 | 2 |
| 2004 | 0 | 2 | 2 |
| 2005 | 0 | 8 | 8 |
| 2006 | 0 | 5 | 5 |
| 2007 | 0 | 6 | 6 |
| 2008 | 0 | 11 | 11 |
| 2009 | 0 | 11 | 11 |
| 2010 | 0 | 13 | 13 |
| 2011 | 5 | 15 | 20 |
| 2012 | 7 | 8 | 15 |
| 2013 | 6 | 6 | 12 |
| 2014 | 11 | 8 | 19 |
| 2015 | 5 | 8 | 13 |
| 2016 | 3 | 12 | 15 |
| 2017 | 6 | 10 | 16 |
| 2018 | 9 | 10 | 19 |
| 2019 | 16 | 11 | 27 |
| 2020 | 15 | 18 | 33 |
| 2021 | 24 | 7 | 31 |
| 2022 | 7 | 21 | 28 |
| 2023 | 5 | 23 | 28 |
| 2024 | 25 | 15 | 40 |
| 2025 | 22 | 7 | 29 |
| 2026 | 20 | 6 | 26 |
To return to the timeline,
click here.
Below are the most recent publications written about "Antibodies, Monoclonal, Humanized" by people in Profiles.
-
Baseline and placebo-related imaging, cerebrospinal fluid, plasma biomarker, and cognitive findings in unimpaired PSEN1 E280A mutation carriers and non-carriers in the Alzheimer's Prevention Initiative Autosomal Dominant Alzheimer's Disease Colombia Trial. EBioMedicine. 2026 Aug; 130:106390.
-
Artificial intelligence-guided analysis of the tumor microenvironment predicts response to pembrolizumab in rare tumors. J Immunother Cancer. 2026 Jun 24; 14(6).
-
Dupilumab versus placebo in adults and adolescents with eosinophilic gastritis (DEGAS): a double-blind, placebo-controlled, phase 2, multicentre, randomised controlled trial. Lancet Gastroenterol Hepatol. 2026 Aug; 11(8):672-688.
-
Biomarker study of pembrolizumab in patients with advanced rare cancers. Cell Rep Med. 2026 Jun 16; 7(6):102827.
-
THRIVE: A Phase 3, Randomized, Double-Masked, Placebo-Controlled Study of Veligrotug for Active Thyroid Eye Disease. Ophthalmology. 2026 Sep; 133(9):1085-1096.
-
Maternal RSV Vaccination, Infant Nirsevimab, or Both: Interim Analysis of a Randomized Trial. Pediatrics. 2026 Jun 01; 157(6).
-
Five-year survival with tebentafusp in metastatic uveal melanoma. Ann Oncol. 2026 Sep; 37(9):1266-1277.
-
Safety and efficacy of astegolimab for COPD with frequent exacerbations regardless of baseline blood eosinophil counts (ALIENTO and ARNASA): randomised, double-blind, placebo-controlled, phase 2b and 3 trials. Lancet. 2026 May 23; 407(10543):2027-2039.
-
Highlights of Cardiovascular Disease Prevention Studies Presented at the 2026 American College of Cardiology Conference. Curr Atheroscler Rep. 2026 May 16; 28(1).
-
Imbalance Between CD44 and STAT3 Enhances Spheroid Viability and Impairs Pembrolizumab Response in Urothelial Cancer. Anticancer Res. 2026 May; 46(5):2445-2453.